Wells Fargo
NVCT icon

Wells Fargo’s Nuvectis Pharma NVCT Stock Holding History

Wells Fargo’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$43.4K Sell
5,619
-11,310
-67% -$96.9K ﹤0.01% 5499
2025
Q4 		$128K Buy
16,929
+9,022
+114% +$58.8K ﹤0.01% 5284
2025
Q3 		$47.6K Buy
7,907
+1,254
+19% +$8.62K ﹤0.01% 5566
2025
Q2 		$49.7K Buy
+6,653
New +$60.3K ﹤0.01% 5506
2024
Q2 		– Sell
-2,200
Closed -$18K – 7291
2024
Q1 		$18K Buy
2,200
+298
+16% +$2.53K ﹤0.01% 5604
2023
Q4 		$15.9K Buy
1,902
+437
+30% +$3.9K ﹤0.01% 5717
2023
Q3 		$18.9K Sell
1,465
-1,380
-49% -$20K ﹤0.01% 5623
2023
Q2 		$45.4K Buy
2,845
+2,820
+11,280% +$45K ﹤0.01% 5459
2023
Q1 		$328 Hold
25
– – ﹤0.01% 6640
2022
Q4 		$188 Buy
25
+1
+4% +$7 ﹤0.01% 6634
2022
Q3 		$0 Buy
24
+3
+14% +$28 ﹤0.01% 7145
2022
Q2 		$0 Buy
21
+1
+5% +$12 ﹤0.01% 7277
2022
Q1 		$0 Buy
+20
New +$139 ﹤0.01% 7584

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Wells Fargo's NVCT Position: Q1 2026 in Review

Wells Fargo reduced its Nuvectis Pharma (NVCT) stake by 67% in Q1 2026, selling an estimated $96.9K and leaving 5,619 shares worth $43.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5499.

Wells Fargo first reported a position in NVCT in Q1 2022 and has held it in 13 quarters since. The position peaked at $128K in Q4 2025. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Wells Fargo held 5,619 shares of Nuvectis Pharma worth $43.4K as of Q1 2026.
  • Wells Fargo sold 11,310 Nuvectis Pharma shares in Q1 2026, an estimated $96.9K.
  • Nuvectis Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #5499 holding.
  • Wells Fargo first reported a position in Nuvectis Pharma in Q1 2022 and has held it in 13 quarters since.
  • Wells Fargo's Nuvectis Pharma position peaked at $128K in Q4 2025.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.